Sleep apnea and weight: how OSA is measured and diagnosed, how much weight change matters, treatment options, Zepbound trial results and safety, and Medicare coverage.
Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.
Key facts
- Who to ask
- Bariatric surgery, Obesity medicine, Primary care
- Also called
- obstructive sleep apnea, OSA, sleep apnea weight loss, zepbound sleep apnea, snoring and weight
Key takeaways
- In a 4-year study of 690 adults, a 10% weight loss was linked to a 26% drop in breathing pauses per hour, and a 10% gain to a 32% rise.[4]
- The FDA approved Zepbound on December 20, 2024 as the first medicine for moderate to severe OSA in adults with obesity.[5]
- In SURMOUNT-OSA, tirzepatide reduced the AHI by 25 to 29 events per hour vs about 5 with placebo, and 42% to 50% reached remission or mild OSA.[6]
- PAP devices remain the most common treatment; oral appliances, surgery including nerve stimulation, and lifestyle measures are other options.[2]
- Medicare beneficiaries with moderate to severe OSA use their Part D plan for Zepbound rather than the GLP-1 Bridge (checked 2026-10-06).[11]
In short: Obstructive sleep apnea (OSA) happens when the upper airway is blocked again and again during sleep, causing pauses in breathing. Obesity is one of its main risk factors, and weight matters a lot: in a long-term study, a 10% weight loss was linked to a 26% drop in the number of breathing pauses per hour. On December 20, 2024 the FDA approved Zepbound (tirzepatide) as the first medicine for moderate to severe OSA in adults with obesity. CPAP and other treatments remain the foundation, and only a sleep study can diagnose OSA, so the first step is talking to a clinician.
This page is general education to help you understand sleep apnea and how weight fits in. It is not a diagnosis or personal advice. If you snore loudly, stop breathing in your sleep or feel very sleepy during the day, please get evaluated: untreated sleep apnea raises the risk of serious problems, and drowsy driving is dangerous.
Weight and sleep apnea
- 26%fewer breathing pauses per hour (AHI) with a 10% weight lossPeppard PE et al., JAMA 2000
- 32%more breathing pauses per hour with a 10% weight gainPeppard PE et al., JAMA 2000
- 6 timeshigher risk of developing moderate to severe sleep-disordered breathing with a 10% weight gainPeppard PE et al., JAMA 2000
- Dec 20, 2024FDA approves Zepbound, the first medicine for moderate to severe OSA in adults with obesityU.S. Food and Drug Administration
Checked on October 6, 2026
What sleep apnea is
The National Heart, Lung, and Blood Institute (NHLBI) describes sleep apnea as a common condition in which breathing stops and restarts many times during sleep. There are two main types. Obstructive sleep apnea, the most common, happens when the upper airway becomes blocked. Central sleep apnea happens when the brain does not send the signals needed to breathe. This page is about obstructive sleep apnea, the type most closely linked to weight.
The NHLBI lists the common signs as snoring, gasping for air during sleep, excessive daytime sleepiness and poor sleep quality. Often a bed partner notices the pauses first. Untreated, sleep apnea can cause problems with concentration, memory and behavior control and raises the risk of stroke and heart attack, according to the NHLBI.
How severity is measured: the AHI
Sleep studies count the apnea-hypopnea index (AHI): the number of times per hour that breathing stops (apnea) or becomes very shallow (hypopnea). In the trials that led to Zepbound’s approval, moderate to severe OSA meant an AHI of 15 or more events per hour, obesity meant a BMI of 30 or more (27 or more in Japan), and the people enrolled averaged about 50 events per hour. The trials counted an AHI under 5 as remission and 5 to 14 as mild OSA. Your sleep specialist will interpret your own numbers along with your symptoms.
Why weight matters
Obesity heads the NHLBI’s list of risk factors for obstructive sleep apnea, along with large tonsils and hormonal changes. The NIDDK lists sleep apnea among the health risks of overweight and obesity. The strongest data on how much weight change matters come from the Wisconsin Sleep Cohort, published in JAMA in 2000. Researchers followed 690 adults for four years and measured the AHI at the start and end:
| Item | Value |
|---|---|
| 10% weight gain (AHI increase) | 32% |
| 10% weight loss (AHI decrease) | 26% |
690 adults followed for 4 years. An observational study: it shows a strong link, not a promise for any one person.
Source: Peppard PE et al., JAMA 2000 (Wisconsin Sleep Cohort) (checked on October 6, 2026)
A 10% weight gain was linked to a 32% increase in AHI and a sixfold higher risk of developing moderate to severe sleep-disordered breathing, while a 10% loss was linked to a 26% decrease. The authors concluded that even modest weight control is likely to help manage sleep apnea. Sleep and weight also influence each other in the other direction: the NIDDK notes that too little sleep may increase hunger and calorie intake. Our how to lose weight hub brings the basics together.
How sleep apnea is diagnosed
The NHLBI explains that a clinician will ask about your symptoms, risk factors and family history and may refer you to a sleep specialist or sleep center. A sleep study shows which type of sleep apnea you have and how serious it is. A sleep diary helps track sleep and daytime sleepiness, and the clinician may also order tests to look for related conditions, such as thyroid problems or PCOS.
From snoring to a treatment plan
- Notice the signsLoud snoring, gasping, pauses a partner sees, daytime sleepiness.
- See a clinicianReview symptoms, medicines, alcohol use and other conditions.
- Sleep studyThe type of study is chosen by your clinician or sleep specialist.
- ResultsAHI and oxygen levels set the type and severity.
- Treatment planBreathing device, oral appliance, weight plan, medicine or surgery, often combined.
Treatment options
The NHLBI describes several treatments, and many people use more than one:
- Positive airway pressure (PAP). The most common treatment. CPAP gives constant air pressure through the nose or mouth to keep the airway open; BPAP varies the pressure between breathing in and out; APAP adjusts itself automatically. Side effects can include congestion, nosebleeds and dry mouth.
- Oral appliances. Custom-fitted mouthpieces that hold the lower jaw forward (mandibular repositioning) or keep the tongue in place.
- Surgery. Options include an implanted hypoglossal nerve stimulator placed under the skin of the chest, removal of tonsils or other tissue, jaw advancement surgery, and weight-loss (bariatric) surgery for people with obesity.
- Medicine. One FDA-approved injectable weight-management medicine treats moderate to severe OSA in adults with obesity, together with diet and activity changes (see the next section).
- Myofunctional therapy. Exercises for the mouth and face muscles that strengthen and reposition the tongue.
- Lifestyle. The NHLBI lists regular physical activity, a healthy weight, sleeping on your side, limiting alcohol and caffeine, and quitting smoking.
Zepbound for sleep apnea: what the label and trials say
The FDA approved Zepbound (tirzepatide) on December 20, 2024 to treat moderate to severe OSA in adults with obesity, used with a reduced-calorie diet and increased physical activity. It is the first medicine approved for this use. It is not approved for OSA in people without obesity, and it does not replace a sleep study or a PAP device unless your sleep specialist says so. Our tirzepatide page explains how the molecule works.
The approval rests on the two SURMOUNT-OSA trials, published in the New England Journal of Medicine in 2024. A total of 469 adults with obesity and moderate to severe OSA, and without type 2 diabetes, were randomly assigned to the highest tolerated weekly dose of tirzepatide (10 or 15 mg) or placebo for 52 weeks. Trial 1 (234 people) enrolled people not using PAP; trial 2 (235 people) enrolled people using PAP. Average AHI at the start was 51.5 and 49.5 events per hour.
| Item | Tirzepatide | Placebo |
|---|---|---|
| Trial 1 (not using PAP) | 25.3 events per hour | 5.3 events per hour |
| Trial 2 (using PAP) | 29.3 events per hour | 5.5 events per hour |
Reduction in AHI from about 50 events per hour at the start. In percent: -50.7% and -58.7% with tirzepatide vs -3.0% and -2.5% with placebo.
Source: Malhotra A et al., NEJM 2024 (SURMOUNT-OSA) (checked on October 6, 2026)
| Item | Tirzepatide | Placebo |
|---|---|---|
| Remission or mild OSA, trial 1 | 42.2% | 15.9% |
| Remission or mild OSA, trial 2 | 50.2% | 14.3% |
| Weight lost, trial 1 | 17.7% | 1.6% |
| Weight lost, trial 2 | 19.6% | 2.3% |
Remission or mild OSA = AHI under 5, or 5 to 14 with an Epworth Sleepiness Scale score of 10 or less.
Source: Malhotra A et al., NEJM 2024 (SURMOUNT-OSA) (checked on October 6, 2026)
Tirzepatide also improved oxygen measures, sleep-related symptoms, a blood marker of inflammation (hsCRP) and systolic blood pressure. The most common side effects were digestive and mostly mild to moderate, usually during the dose increases: in trial 1, nausea was reported by 25.4% on tirzepatide versus 10.0% on placebo and diarrhea by 26.3% versus 12.5%.
Safety on the Zepbound label
Zepbound has a boxed warning about thyroid C-cell tumors seen in rodents and is not used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. The label also warns about severe stomach reactions, kidney injury from dehydration, gallbladder disease, pancreatitis, allergic reactions, low blood sugar, diabetic eye complications and aspiration during anesthesia or deep sedation, and says pens must never be shared. It can make birth control pills less effective after starting and after each dose increase. In the pooled weight trials, nausea was reported by 28% to 29% of people and diarrhea by 19% to 23%, depending on dose. Read Zepbound side effects and GLP-1 side effects for the full picture.
Other weight approaches and sleep apnea
Any approach that produces meaningful weight loss may help, which is why the NHLBI lists weight management and bariatric surgery among treatments. A structured lifestyle program, other FDA-approved weight medicines, or bariatric surgery may be considered for weight, although only Zepbound carries an OSA indication. The NHLBI also advises limiting alcohol and caffeine; see our keep it off hub for habits that support both sleep and weight. Strength and activity help too: our walking guide is an easy start.
Cost and insurance
Ask your plan before the sleep study and before getting a PAP device what is covered and what you will pay. For Zepbound, Lilly listed self-pay prices of $299 a month for the 2.5 mg dose, $399 for 5 mg and $449 for 7.5 mg to 15 mg when refills are on time, and a savings card for people with commercial coverage (checked on 2026-10-06). On Medicare, CMS says beneficiaries with moderate to severe OSA are not eligible for the temporary GLP-1 Bridge and use their regular Part D plan instead. See our Zepbound cost page and the insurance hub.
When to see a doctor
See a clinician if you snore loudly, if someone has seen you stop breathing or gasp in your sleep, if your sleep feels poor, or if you feel very sleepy during the day, especially while driving. Sleep apnea is also worth asking about if you have high blood pressure, type 2 diabetes or PCOS. A primary care clinician can start the workup and refer you to a sleep specialist. The conditions hub covers related conditions.
Overview
Obstructive sleep apnea is a common condition in which the upper airway is repeatedly blocked during sleep, causing breathing to stop and restart. Obesity is a main risk factor; in the Wisconsin Sleep Cohort a 10% weight loss was linked to a 26% lower AHI and a 10% gain to a 32% higher AHI. Treatments include PAP devices, oral appliances, surgery, weight management and, since December 20, 2024, Zepbound for moderate to severe OSA in adults with obesity.
Signs
- Loud snoring
- Gasping or pauses in breathing during sleep (often noticed by a partner)
- Excessive daytime sleepiness
- Poor sleep quality; problems with concentration and memory
Tests a clinician may order
- Sleep history, symptoms and risk factors
- Sleep study measuring the apnea-hypopnea index and oxygen levels
- Sleep diary
- Tests for related conditions such as thyroid problems or PCOS
What lifestyle research shows
Peppard et al. (JAMA 2000, 690 adults, 4 years): a 10% weight loss was linked to a 26% decrease in AHI, and a 10% gain to a 32% increase and a sixfold higher risk of moderate to severe sleep-disordered breathing. NHLBI lifestyle measures: physical activity, healthy weight, side sleeping, limiting alcohol and caffeine, quitting smoking.
When to see a doctor
See a clinician for loud snoring, observed pauses or gasping in sleep, poor sleep or daytime sleepiness, especially while driving, and if you have high blood pressure, type 2 diabetes or PCOS.
Treatments discussed
FDA approved for weight managementPrescriptionInjectionZepbound (tirzepatide): uses, side effects, cost and FDA statusTirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro) · Injection · Weekly
FDA approved for weight managementPrescriptionInjectionTirzepatide: how the dual GIP/GLP-1 drug works (Zepbound, Mounjaro)Injection · Weekly
SurgicalGastric Sleeve Surgery: eligibility, results, risks and costSurgical · 2+ weeks
SurgicalGastric Bypass: how it works, results and long-term careSurgical · 2+ weeksResearch mentioning it
10 Innovations That Changed Weight Loss (2016 to 2026)Ten weight-loss innovations from 2016 to 2026, listed by date: the new food label, Plenity, Imcivree,…
Retatrutide Phase 3 Results ExplainedRetatrutide's Phase 3 TRIUMPH results explained: weight loss by dose and trial, the two estimands, side…
A History of Weight-Loss Drugs: From Thyroid Pills and Fen-Phen to GLP-1sA history of weight-loss drugs from FDA records: dinitrophenol, amphetamines, fen-phen, sibutramine and Belviq withdrawals, orlistat,…Related guides
Conditions Linked to Weight: what to know and who to askThe health conditions linked to weight, from insulin resistance and type 2 diabetes to sleep apnea,…
Bariatric Surgery: types, eligibility and life afterBariatric surgery explained: sleeve, bypass, duodenal switch and band compared, the 2022 eligibility guidelines, results, risks,…
How to Lose Weight: every proven approach in one placeHow to lose weight: the calorie deficit, food, activity, sleep and habits with the best evidence,…Tools for this topic
BMI Calculator for Adults (and what BMI cannot tell you)Free BMI calculator for adults with CDC categories, plus what BMI cannot tell you, why waist…
Weight-Loss Timeline Calculator: a conservative goal-date estimateFree weight loss calculator: a conservative goal-date range that accounts for your body needing less energy…Questions to ask your doctor or pharmacist
- Do my symptoms warrant a sleep study, and should it be at home or in a sleep center?
- What do my AHI and oxygen results mean, and how severe is my sleep apnea?
- Which treatment fits me best: PAP, an oral appliance, weight management, medicine or surgery?
- If I lose weight or start Zepbound, when should I have a repeat sleep study?
- How should my sleep apnea be handled if I need surgery or sedation?
- What will my plan cover for the sleep study, PAP equipment and medicine?
Frequently asked questions
Can losing weight cure sleep apnea?
Weight loss can reduce sleep apnea a lot, and some people reach remission, but not everyone does. In the Wisconsin Sleep Cohort a 10% loss was linked to 26% fewer breathing pauses per hour. A repeat sleep study is the only way to know where you stand.
How much weight do I need to lose to help sleep apnea?
There is no fixed number. Studies show that even modest weight change matters, and in SURMOUNT-OSA people lost about 18% to 20% of their weight on tirzepatide with large AHI reductions. Your sleep specialist can tell you how your results change.
Is Zepbound approved for sleep apnea?
Yes, for moderate to severe obstructive sleep apnea in adults with obesity, together with diet and activity changes. It was approved on December 20, 2024. It is not approved for OSA in people without obesity.
Can I stop using my CPAP if I take Zepbound?
Do not stop on your own. In SURMOUNT-OSA trial 2, people kept using PAP while taking tirzepatide. Whether and when PAP can be changed is a decision for your sleep specialist, usually after a new sleep study.
What is the AHI?
The apnea-hypopnea index is the number of times per hour that breathing stops or becomes very shallow during sleep. In the Zepbound trials, moderate to severe OSA meant 15 or more events per hour; remission meant fewer than 5.
Does Medicare cover Zepbound for sleep apnea?
CMS says beneficiaries with moderate to severe OSA are not eligible for the temporary GLP-1 Bridge and use their regular Part D plan instead. Coverage and cost depend on the plan (checked October 6, 2026).
Can thin people have sleep apnea?
Yes. The NHLBI also lists large tonsils and hormonal changes as risk factors, and central sleep apnea is not caused by weight. Anyone with the symptoms should be evaluated.
Does sleep apnea cause weight gain?
Poor sleep may increase hunger, calorie intake and cravings for less healthy foods, according to the NIDDK, which can make weight harder to manage. Treating sleep apnea is one part of a weight plan, not a replacement for one.
What are the side effects of Zepbound for sleep apnea?
Mostly digestive and usually mild to moderate during dose increases. In SURMOUNT-OSA trial 1, nausea affected 25.4% vs 10.0% on placebo and diarrhea 26.3% vs 12.5%. The label has a boxed warning about thyroid C-cell tumors in rodents and other warnings.
References
- Sleep Apnea. National Heart, Lung, and Blood Institute (NIH), 2025. (accessed October 6, 2026) Government page
- Sleep Apnea: Treatment. National Heart, Lung, and Blood Institute (NIH). (accessed October 6, 2026) Government page
- Sleep Apnea: Diagnosis. National Heart, Lung, and Blood Institute (NIH). (accessed October 6, 2026) Government page
- Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal Study of Moderate Weight Change and Sleep-Disordered Breathing. JAMA, 2000. doi:10.1001/jama.284.23.3015 · PMID 11122588 (accessed October 6, 2026) Other
- FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food and Drug Administration, 2024. (accessed October 7, 2026) Government page
- Malhotra A, Grunstein RR, Fietze I, et al.. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine, 2024. doi:10.1056/NEJMoa2404881 · PMID 38912654 · NCT05412004 (accessed October 6, 2026) Randomized trial
- ZEPBOUND (tirzepatide) injection: prescribing information. Eli Lilly and Company, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- Health Risks of Overweight and Obesity. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). (accessed October 6, 2026) Government page
- Factors Affecting Weight and Health. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). (accessed October 6, 2026) Government page
- Zepbound coverage and savings. Eli Lilly and Company. (accessed October 6, 2026) Other
- Medicare GLP-1 Bridge: Information for Part D Plans. Centers for Medicare & Medicaid Services. (accessed October 6, 2026) Government page
Facts checked on October 6, 2026
Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.